News und Analysen

Gene editing is one of the most revolutionary trends in modern medicine. The potential to swap out a person's genes to eliminate and prevent diseases is here, and investors are keenly looking at

Gene editing is one of the most revolutionary trends in modern medicine. The potential to swap out a person's genes to eliminate and prevent diseases is here, and investors are keenly looking at

Gene editing is one of the most revolutionary trends in modern medicine. The potential to swap out a person's genes to eliminate and prevent diseases is here, and investors are keenly looking at

Smart investors are continually looking for new investment ideas. Sometimes, those ideas are so good that they're hard to pass up.

Three Motley Fool contributors think they've picked some stocks

Smart investors are continually looking for new investment ideas. Sometimes, those ideas are so good that they're hard to pass up.

Three Motley Fool contributors think they've picked some stocks

Smart investors are continually looking for new investment ideas. Sometimes, those ideas are so good that they're hard to pass up.

Three Motley Fool contributors think they've picked some stocks

Early on in the pandemic, Moderna and Pfizer beat smaller rival Novavax (NASDAQ: NVAX) to market with their coronavirus vaccines by a year or more in some countries. This head start offered them the

There are excellent reasons to invest in dividend stocks beyond their regular payouts. Growing a dividend requires companies to deliver solid financial results regularly, and the longer a

Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO) are two top pharmaceutical companies that are pursuing growth opportunities. Pfizer is looking to build up and diversify its business as its COVID

Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO) are two top pharmaceutical companies that are pursuing growth opportunities. Pfizer is looking to build up and diversify its business as its COVID

Shares of Coherus BioSciences (NASDAQ: CHRS) rose 9.4% on Thursday after the biotech resubmitted a biologic license application (BLA) supplement for a key product to the U.S. Food and Drug

Investing wisdom tells us to buy low, but what exactly constitutes a "low" point? Consider the case of Regeneron (NASDAQ: REGN), a biotech company that has beaten the market in recent years. Despite

Investing wisdom tells us to buy low, but what exactly constitutes a "low" point? Consider the case of Regeneron (NASDAQ: REGN), a biotech company that has beaten the market in recent years. Despite

Investing wisdom tells us to buy low, but what exactly constitutes a "low" point? Consider the case of Regeneron (NASDAQ: REGN), a biotech company that has beaten the market in recent years. Despite

UnitedHealth Group (NYSE: UNH) is one of the largest healthcare companies in the world. It's already a top health insurer in the U.S., but that doesn't mean the company isn't working to be even

UnitedHealth Group (NYSE: UNH) is one of the largest healthcare companies in the world. It's already a top health insurer in the U.S., but that doesn't mean the company isn't working to be even

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.

Meet the

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.

Meet the

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.

Meet the

A fairly uninspiring set of quarterly results pushed AngioDynamics (NASDAQ: ANGO) stock down in value on Wednesday. The medical device and technology company saw its share price dip by almost 3% on